Study of comparative bioavailability of omeprazole pellets

Area of Science:

• Pharmacokinetics and Drug Bioavailability
• Pharmaceutical Sciences
• Clinical Pharmacology

Background:

• Omeprazole is a widely used proton pump inhibitor for treating acid-related gastrointestinal disorders.
• Ensuring therapeutic equivalence between generic and reference formulations is crucial for patient safety and treatment efficacy.
• Bioequivalence studies are essential for regulatory approval of generic drugs.

Purpose of the Study:

• To assess the bioequivalence of a laboratory-based omeprazole formulation compared to the commercial reference formulation, Zimor.
• To determine if the test omeprazole formulation exhibits comparable pharmacokinetic profiles to the reference product.
• To provide data supporting the interchangeability of the test omeprazole formulation with Zimor.

Main Methods:

• A 2-period, 2-sequence crossover study design was employed.
• A validated high-performance liquid chromatographic (HPLC) method was utilized for quantifying omeprazole in biological samples.
• Bioequivalence was established by calculating 90% confidence intervals (CI) for the ratio of total area under the concentration-time curve (AUC) between test and reference formulations.

Main Results:

• Omeprazole content was found to be comparable across all tested formulations.
• The 95% CI for the ratio of total AUCs fell within the accepted bioequivalence range of 0.80 to 1.25.
• No significant carryover effect was observed, validating the study design.

Conclusions:

• The laboratory-based omeprazole formulation is bioequivalent to the reference formulation, Zimor.
• The comparable bioavailability suggests therapeutic equivalence between the test and reference omeprazole products.
• This study supports the potential use of the test omeprazole formulation as a generic alternative to Zimor.